Lotus Pharmaceutical Co logo

1795 - Lotus Pharmaceutical Co Share Price

TWD72.7 -1.3  -1.8%

Last Trade - 5:30am

Mid Cap
Market Cap £467.5m
Enterprise Value £616.1m
Revenue £276.2m
Position in Universe 1357th / 6141
Unlock 1795 Revenue
Relative Strength (%)
1m +9.03%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
2,310 5,522 5,903 6,424 6,429 9,175 10,697 11,870 +31.8%
+337.1 +717.7 +31.1 +18.8
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, LotusPharmaceutical Co Ltd revenues increased 19% to NT$7.6B.Net income increased 35% to NT$708.8M. Revenues reflectWestern Medicine Manufacture segment increase from NT$4.11Bto NT$72.5B. Net income benefited from Western MedicineManufacture segment income increase of 28% to NT$1.14B,Eliminations segment income totaling NT$0K vs. loss ofNT$9.3M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


1795 Revenue Unlock 1795 Revenue

Net Income

1795 Net Income Unlock 1795 Revenue

Normalised EPS

1795 Normalised EPS Unlock 1795 Revenue

PE Ratio Range

1795 PE Ratio Range Unlock 1795 Revenue

Dividend Yield Range

1795 Dividend Yield Range Unlock 1795 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
1795 EPS Forecasts Unlock 1795 Revenue
Profile Summary

Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated June 30, 1966
Public Since December 13, 2004
No. of Shareholders: 19,977
No. of Employees: 1,099
Sector Healthcare
Industry Pharmaceuticals
Index Taiwan SE Weighted ,
Exchange Taiwan Stock Exchange
Shares in Issue 245,353,964
Free Float (0.0%)
Eligible for
1795 Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for 1795
Upcoming Events for 1795
Frequently Asked Questions for Lotus Pharmaceutical Co
What is the Lotus Pharmaceutical Co share price?

As of 5:30am, shares in Lotus Pharmaceutical Co are trading at TWD72.7, giving the company a market capitalisation of £467.5m. This share price information is delayed by 15 minutes.

How has the Lotus Pharmaceutical Co share price performed this year?

Shares in Lotus Pharmaceutical Co are currently trading at TWD72.7 and the price has moved by -21.78% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Lotus Pharmaceutical Co price has moved by -40.64% over the past year.

What are the analyst and broker recommendations for Lotus Pharmaceutical Co?

Of the analysts with advisory recommendations for Lotus Pharmaceutical Co, there are there are currently 4 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Lotus Pharmaceutical Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Lotus Pharmaceutical Co next release its financial results?

Lotus Pharmaceutical Co is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Lotus Pharmaceutical Co dividend yield?

Lotus Pharmaceutical Co does not currently pay a dividend.

Does Lotus Pharmaceutical Co pay a dividend?

Lotus Pharmaceutical Co does not currently pay a dividend.

When does Lotus Pharmaceutical Co next pay dividends?

Lotus Pharmaceutical Co does not currently pay a dividend.

How do I buy Lotus Pharmaceutical Co shares?

To buy shares in Lotus Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Lotus Pharmaceutical Co?

Shares in Lotus Pharmaceutical Co are currently trading at TWD72.7, giving the company a market capitalisation of £467.5m.

Where are Lotus Pharmaceutical Co shares listed? Where are Lotus Pharmaceutical Co shares listed?

Here are the trading details for Lotus Pharmaceutical Co:

Country of listing: Taiwan
Exchange: TAI
Ticker Symbol: 1795
What kind of share is Lotus Pharmaceutical Co?

Based on an overall assessment of its quality, value and momentum, Lotus Pharmaceutical Co is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Lotus Pharmaceutical Co share price forecast 2021?

Shares in Lotus Pharmaceutical Co are currently priced at TWD72.7. At that level they are trading at 49.55% discount to the analyst consensus target price of 0.00.

Analysts covering Lotus Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of 4.517 for the next financial year.

How can I tell whether the Lotus Pharmaceutical Co share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lotus Pharmaceutical Co. Over the past six months, the relative strength of its shares against the market has been -27.87%. At the current price of TWD72.7, shares in Lotus Pharmaceutical Co are trading at -7.61% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Lotus Pharmaceutical Co PE Ratio?

The Lotus Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 16.76. The shares are currently trading at TWD72.7.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Lotus Pharmaceutical Co?

Lotus Pharmaceutical Co's management team is headed by:

Arni Hardarson - DRC
Thor Kristjansson - DRC
Benjamin Ku - IND
Robert Wessman - CHM
Petar Vazharov - GMG
Yi-Lin Tien - CFO
Bjartur Shen - DGM
Stanley Gu - OTH
Zenon Zdunek - DGM
Joel Morales - DRC
Manish Chawla - DGM
Hirofumi Imai - DRC
Rongxin Chen - DGM
Who are the major shareholders of Lotus Pharmaceutical Co?

Here are the top five shareholders of Lotus Pharmaceutical Co based on the size of their shareholding:

Alvogen Emerging Markets Holdings Ltd. Corporation
Percentage owned: 61.58% (151.1m shares)
Fuji Pharma Co Ltd Corporation
Percentage owned: 2% (4.91m shares)
Fiera Capital Emerging Markets Fund Mutual Fund
Percentage owned: 1.96% (4.82m shares)
Fiera Capital Corporation Investment Advisor/Hedge Fund
Percentage owned: 1.96% (4.82m shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 1.58% (3.87m shares)
Similar to 1795
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.